ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
BenevolentAI wins Innovation Award at 2020 Scrip Awards
BenevolentAI wins the Innovation Award at the prestigious 2020 Scrip Awards for our work in artificial intelligence applied drug discovery.
Data published in Science Advances shows baricitinib reduces COVID-19 morbidity and mortality
Research published in Science Advances supports BenevolentAI’s AI-generated hypothesis from late January for baricitinib as a treatment for COVID-19.
Investival Showcase Virtual w/ Jackie Hunter
Join BenevolentAI’s Board Director, Jackie Hunter, at the Investival Showcase for a discussion of cross-sector approaches to solving healthcare’s biggest challenges.
WHAT WE DO
Why it matters
Data Diversity initiative
Company Registration: 09781806
Terms & Conditions
Privacy & Cookies Policy